title: [A severe cutaneous anthrax case complicated with sepsis in Bursa, Turkey].
abstract: Anthrax is a zoonotic infection caused by Bacillus anthracis. Although the incidence of disease has been decreasing in Turkey, it is still endemic in some regions of the country. The cutaneous form of disease is the most common clinical form, usually benign and rarely causes bacteriemia and sepsis. In this report, a case of cutaneous anthrax complicated with sepsis where B.anthracis was isolated from blood and wound cultures, was presented. A 53-years-old male living in Bursa province (northwestern Turkey), admitted to the emergency ward with high fever and a lesion on the right arm. His history indicated that he is dealing with livestock breeding and injured his arm during slaughtering of a sick lamb. The infection started as a black colored painless ulcer with 2 cm in diameter on his right elbow. The case was hospitalized and penicillin G therapy was started with the preliminary diagnosis of anthrax. Bullous lesions occurred around the wound, got necrosis and integrated with the first lesion. Gram stained slides from the bullous lesions revealed capsulated gram-positive bacilli under light microscope. Gram-positive bacilli were also isolated from bullous lesions and the blood cultures. The isolates were identified and confirmed as B.anthracis by conventional and molecular methods. Antibiotic susceptibility tests were performed by E-test method and the isolates were found to be susceptible to ampicillin, tetracyclin, tigecyclin, ciprofloxacin, levofloxacin, gentamycin, chloramphenicol, erythromycin, clarithromycin, vancomycin, linezolid, daptomycin and rifampicin. The lesion became surrounded by an extensive erythema and edema and expanded to the whole arm. Moxifloxacin was initiated due to the fact that clinical progress. During the second week of the therapy, a black colored scar was observed on the wound while hyperemia and edema regressed. The necrotic tissue debridated to accelerate healing and rest of the skin defect was planned for reconstruction. The patient who had septicaemia and disseminated cellulitis was discharged after his treatment continued for 14 days. Multiple-locus variable-number tandem repeat analysis method was used for molecular epidemiological investigation. The strains isolated from the patient were identified as genotype (GK) 43 classified in A3.a major cluster, and found to be identical to those strains isolated from animals in different provinces located at central and eastern Anatolia of Turkey. In conclusion, the risk of sepsis must be considered in patients with cutaneous anthrax with appropriate follow-up and treatment plan.
authors: Public Health Institution of Turkey, National High Risk Pathogens Reference Laboratory, Ankara, Turkey. mdskilic2003@yahoo.com.
authors: Gül
authors: G
authors: Durmuş
authors: Murat
authors: M
authors: Yeşilyurt
authors: Alper
authors: A
authors: Karagöz
authors: Canan
authors: C
authors: Demir
authors: Nilüfer
authors: N
authors: Eren
authors: Selçuk
authors: S
authors: Kılıç
mesh_terms: D000818:Animals; D000881:Anthrax / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use; D001408:Bacillus anthracis / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification; D003646:Debridement; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D010400:Penicillin G / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy / Q000382:microbiology*; D012756:Sheep; D017192:Skin Diseases, Bacterial / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D014421:Turkey; D014947:Wounds and Injuries / Q000150:complications / Q000382:microbiology; D015047:Zoonoses / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D010400:Penicillin G; D000077266:Moxifloxacin